Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2023 Filed Aug 16, 2023 17:51 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 1,500 | $181.01 | $271,515.00 |
DisclosureSEC source: 0001127602-23-022703 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Plan reported Ownership: Indirect · Douglas Family Trust Disclosed balance after: 250,526 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 9, 2023. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 17:39 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-022774 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,490 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 17:39 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $183.20 | $1,039,646.95 |
DisclosureSEC source: 0001127602-23-022774 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,930 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $181.30 to 183.85. The price reported above reflects the weighted average sale price. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 17:39 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-022774 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| August 01, 2023 Filed Aug 2, 2023 21:30 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 25 | $224.12 | $5,603.00 |
DisclosureSEC source: 0001127602-23-021872 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,186 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 24, 2023. Read SEC document |
| July 17, 2023 Filed Jul 18, 2023 21:02 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 1,500 | $222.22 | $333,330.00 |
DisclosureSEC source: 0001127602-23-020952 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Plan reported Ownership: Indirect · Douglas Family Trust Disclosed balance after: 252,026 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 9, 2023. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 16:13 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-020982 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,165 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 16:13 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $221.27 | $1,255,686.25 |
DisclosureSEC source: 0001127602-23-020982 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,930 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $220.20 to 222.46. The price reported above reflects the weighted average sale price. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 16:13 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-020982 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| July 13, 2023 Filed Jul 14, 2023 16:26 UTC |
Ghoshal KaushikPresident, SaaS Business
|
SaleResMed Common Stock | 500 | $220.00 | $110,000.00 |
DisclosureSEC source: 0001127602-23-020719 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,787 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 17, 2023. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 18:13 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 25 | $217.21 | $5,430.25 |
DisclosureSEC source: 0001127602-23-019888 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,211 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 24, 2023. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:17 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-018903 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,840 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:17 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $217.39 | $1,233,716.06 |
DisclosureSEC source: 0001127602-23-018903 · form4.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,930 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $214.86 to 219.21. The price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:17 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-018903 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 16:02 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 1,500 | $216.27 | $324,405.00 |
DisclosureSEC source: 0001127602-23-018944 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Plan reported Ownership: Indirect · Douglas Family Trust Disclosed balance after: 253,526 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 9, 2023. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 16:20 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,500 | $219.79 | $329,685.00 |
DisclosureSEC source: 0001127602-23-018089 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,729 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2022. F2 · balance_after: Includes 56.7807 shares of ResMed stock purchased on April 28, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 17:18 UTC |
Ghoshal KaushikPresident, SaaS Business
|
SaleResMed Common Stock | 500 | $220.00 | $110,000.00 |
DisclosureSEC source: 0001127602-23-018002 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,287 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 17, 2023. F2 · balance_after: Includes 83.0936 shares of ResMed stock purchased on April 28, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 15, 2023 Filed May 16, 2023 22:07 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 1,500 | $232.85 | $349,275.00 |
DisclosureSEC source: 0001127602-23-015793 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Plan reported Ownership: Indirect · Douglas Family Trust Disclosed balance after: 255,026 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 9, 2023. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:10 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-015838 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,515 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:10 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $232.10 | $1,317,190.77 |
DisclosureSEC source: 0001127602-23-015838 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,930 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $231.02 - $232.78. The price reported above reflects the weighted average sale price. F3 · balance_after: Includes 30.2388 shares of ResMed stock purchased on April 28, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:10 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-015838 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| May 10, 2023 Filed May 12, 2023 23:30 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 12,574 | $233.13 | $2,931,395.48 |
DisclosureSEC source: 0001127602-23-015482 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,942 F1 · kind: The transaction was conducted during an open trading window. Read SEC document |
| May 09, 2023 Filed May 10, 2023 21:16 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,426 | $232.05 | $794,999.87 |
DisclosureSEC source: 0001127602-23-015146 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,516 F1 · kind: The transaction was conducted during an open trading window. F2 · balance_after: Includes 62.3215 shares of ResMed stock purchased on April 28, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 03, 2023 Filed May 4, 2023 23:49 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,500 | $237.64 | $356,460.00 |
DisclosureSEC source: 0001127602-23-014596 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,172 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2022. Read SEC document |
| May 03, 2023 Filed Feb 23, 2024 23:40 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 12,600 | $237.17 | $2,988,374.76 |
DisclosureSEC source: 0001127602-24-006731 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,896 F1 · price: This transaction was executed in multiple trades at prices ranging from $236.40 - $237.94. The price reported above reflects the weighted average sale price. Read SEC document |
| May 01, 2023 Filed May 2, 2023 12:04 UTC |
Ghoshal KaushikPresident, SaaS Business
|
SaleResMed Common Stock | 500 | $239.30 | $119,650.00 |
DisclosureSEC source: 0001127602-23-013991 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,704 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 17, 2023. Read SEC document |
| April 24, 2023 Filed Apr 25, 2023 23:34 UTC |
Ghoshal KaushikPresident, SaaS Business
|
SaleResMed Common Stock | 2,000 | $230.00 | $460,000.00 |
DisclosureSEC source: 0001127602-23-013548 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,204 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 17, 2023. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 01:10 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 1,500 | $224.65 | $336,975.00 |
DisclosureSEC source: 0001127602-23-013175 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Plan reported Ownership: Indirect · Douglas Family Trust Disclosed balance after: 256,526 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 9, 2023. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:59 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-013145 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,190 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:59 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $224.23 | $1,272,526.25 |
DisclosureSEC source: 0001127602-23-013145 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,900 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $222.99 - $225.525. The price reported above reflects the weighted average sale price. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:59 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-013145 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 19:28 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,500 | $218.23 | $327,345.00 |
DisclosureSEC source: 0001127602-23-012530 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,672 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2022. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 19:26 UTC |
Ghoshal KaushikPresident, SaaS Business
|
SaleResMed Common Stock | 500 | $220.00 | $110,000.00 |
DisclosureSEC source: 0001127602-23-012528 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,204 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 17, 2023. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 20:14 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 1,500 | $206.14 | $309,210.00 |
DisclosureSEC source: 0001127602-23-010444 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 258,026 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 9, 2023. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 20:14 UTC |
Douglas Robert AndrewPresident and COO
|
GiftResMed Common Stock | 1,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-010444 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 259,526 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 9, 2023. F2 · kind: Gift of shares to Fidelity Charitable, a donor advised fund. Mr. Douglas has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:40 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-010519 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,865 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:40 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $206.95 | $1,174,450.90 |
DisclosureSEC source: 0001127602-23-010519 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,900 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $205.82 - $208.24. The price reported above reflects the weighted average sale price. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:40 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-010519 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 17:28 UTC |
Ghoshal KaushikPresident, SaaS Business
|
SaleResMed Common Stock | 1,000 | $220.00 | $220,000.00 |
DisclosureSEC source: 0001127602-23-009227 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,704 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 17, 2023. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 17:32 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,500 | $216.69 | $325,035.00 |
DisclosureSEC source: 0001127602-23-009228 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,172 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2022. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:21 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 10,000 | $215.22 | $2,152,196.00 |
DisclosureSEC source: 0001127602-23-006460 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,880 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $215.00 - $215.59. The price reported above reflects the weighted average sale price. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:12 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 1,500 | $213.50 | $320,250.00 |
DisclosureSEC source: 0001127602-23-005682 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 261,445 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes a transfer of shares between direct and indirect holdings on 2/8/2023. Read SEC document |
| February 15, 2023 Filed Feb 16, 2023 20:23 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-005517 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,540 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 15, 2023 Filed Feb 16, 2023 20:23 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $214.83 | $1,219,143.79 |
DisclosureSEC source: 0001127602-23-005517 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,900 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $213.07 - $215.35. The price reported above reflects the weighted average sale price. Read SEC document |
| February 15, 2023 Filed Feb 16, 2023 20:23 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-005517 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 18:53 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 4,000 | $215.00 | $860,000.00 |
DisclosureSEC source: 0001127602-23-005095 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,880 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 03, 2023 Filed Feb 6, 2023 18:55 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,500 | $224.50 | $336,750.00 |
DisclosureSEC source: 0001127602-23-003509 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,672 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 02, 2023 Filed Feb 4, 2023 00:30 UTC |
Drexler KarenDirector
|
SaleResMed Common Stock | 594 | $226.58 | $134,588.52 |
DisclosureSEC source: 0001127602-23-003464 · form4.xml · nonDerivative · entry 1 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,987 Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 21:30 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 1,500 | $220.43 | $330,645.00 |
DisclosureSEC source: 0001127602-23-001652 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 226,208 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 21:28 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-001650 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,215 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.